Insider Stock BuysAnalysis Archive

CFO Bets $722K Against the Tape

Summit's CFO just dropped $722,250 at $14.45 while the stock shows selling pressure across every timeframe. That's contrarian conviction from the money guy who sees the books daily. The technicals are ugly with 80% sell signals and RSI at 36, but insiders on this biotech have been right about 2 out of 3 times in recent months. Risk is real here with support thin at $14.17, but when a CFO backs up the truck this size against momentum, he's seeing something the market isn't pricing in yet.

The Filing

TickerSMMT
CompanySummit Therapeutics Inc.
InsiderManmeet Singh Soni, COO and CFO
Buy amount$722,250
Filing dateJune 4, 2026
ConvictionFavorable · 68/100
Setup typeOversold Bounce

Ultimate members received this analysis in real time.